Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OFIRMEV vs ANHYDRON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
Edema associated with congestive heart failure, cirrhosis of the liver, and renal disease,Hypertension (off-label use)
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Terminal elimination half-life is 60-90 minutes, prolonged in renal impairment (up to 24 hours).
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Partially metabolized by the liver; primarily excreted unchanged in urine.
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
Renal: ~60% unchanged; biliary/fecal: ~40% as metabolites and unchanged drug.
10-25% bound to albumin at therapeutic concentrations.
95% bound, primarily to albumin.
0.8-1.0 L/kg. Indicates distribution into total body water.
0.2-0.3 L/kg, reflecting distribution primarily in extracellular fluid.
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
Oral: ~65% (range 50-80%) due to first-pass metabolism.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
GFR 10-50 m L/min: 50 mg every 12 hours. GFR <10 m L/min: 50 mg every 24 hours or not recommended.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
Mild to moderate hepatic impairment (Child-Pugh A or B): no adjustment. Severe hepatic impairment (Child-Pugh C): avoid use.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
1-2 mg/kg/dose once daily; maximum 100 mg/day.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
Start at 12.5-25 mg once daily; titrate slowly due to risk of hypotension and electrolyte imbalance.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
No FDA black box warning.
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Electrolyte imbalance (hypokalemia, hyponatremia, hypochloremia),Dehydration and hypotension,Ototoxicity (especially with rapid IV administration or renal impairment),Hyperuricemia and gout,Sulfonamide cross-sensitivity in sulfa-allergic patients
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
Anuria,Severe renal failure,Hepatic coma or pre-coma,Severe electrolyte depletion,Hypersensitivity to sulfonamides
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) as hyperkalemia may occur. Limit salt substitutes containing potassium. Grapefruit juice may increase drug absorption; avoid concurrent use. Alcohol may enhance orthostatic hypotension.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
Cyclothiazide (ANHYDRON) is a thiazide diuretic. Use in pregnancy is generally avoided due to potential adverse effects. First trimester: limited data, but thiazides have been associated with an increased risk of congenital anomalies in some studies, including cleft lip/palate and cardiac defects. Second and third trimesters: can cause fetal or neonatal jaundice, thrombocytopenia, electrolyte disturbances, and possibly intrauterine growth restriction. Crosses the placenta. Use only if clearly needed for maternal conditions like hypertension or edema.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
Cyclothiazide is excreted into human breast milk. The milk-to-plasma ratio is not well defined for cyclothiazide but for thiazides generally is around 0.5-1.0. May suppress lactation. Potential for infant adverse effects (e.g., electrolyte disturbances, thrombocytopenia). Use caution in breastfeeding; alternatives are preferred.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
Pharmacokinetic changes in pregnancy (increased plasma volume, renal blood flow, and GFR) may reduce effectiveness of thiazides. No specific dosing adjustment guidelines for cyclothiazide; however, if used, start at lowest effective dose and titrate based on response. Typical adult dose: 2 mg once daily; may adjust to 1-4 mg. Monitor for hypotension and electrolyte imbalances. Avoid in preeclampsia due to decreased placental perfusion.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
ANHYDRON (cyclothiazide) is a thiazide-like diuretic used for hypertension and edema. Monitor serum potassium and glucose levels; hypokalemia and hyperglycemia are common. Use with caution in renal impairment (Cr Cl <30 m L/min). Avoid in patients with anuria or sulfonamide allergy.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
Take exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,May cause dizziness or lightheadedness; rise slowly from sitting or lying down.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat.,Do not stop abruptly without consulting your doctor; gradual dose reduction may be needed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OFIRMEV vs ANHYDRON, answered by our medical review team.
OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. ANHYDRON is a Thiazide Diuretic that works by Inhibits the sodium-potassium-2 chloride (Na-K-2Cl) cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OFIRMEV and ANHYDRON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. The standard adult dose of ANHYDRON is: Oral: 25-100 mg once daily in the morning, or 50-100 mg every other day; maximum 200 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OFIRMEV and ANHYDRON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. ANHYDRON is classified as Category C. Cyclothiazide (ANHYDRON) is a thiazide diuretic. Use in pregnancy is generally avoided due to potential adverse effects. First trimester: limited data, but thiazides have been asso. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.